Gull Laboratories Toxoplasma gondii test cleared:
This article was originally published in Clinica
Executive Summary
Gull Laboratories' Toxo Igg Elisa test for detecting the protozoan, Toxoplasma gondii, has been cleared by the FDA for marketing in the US. Gull, based in Salt lake City, Utah, estimates that the world market for serological tests for Toxoplasma infection, which can cause a range of birth defects in newborns, to be worth approximately $100 million annually.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.